Navigation Links
AMRI Announces Proposed Private Offering of $100 Million Cash Convertible Senior Notes
Date:11/18/2013

ALBANY, N.Y., Nov. 18, 2013 /PRNewswire/ -- Albany Molecular Research, Inc. (NASDAQ: AMRI) ("AMRI") announced its intention to privately offer $100 million principal amount of cash convertible senior notes due 2018, subject to market and other conditions, to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). AMRI also expects to grant the initial purchasers of the notes an option to purchase up to an additional $15 million principal amount of the notes solely to cover over-allotments, if any.

J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint-bookrunning managers for the proposed offering.

The interest rate, conversion rate and other terms of the notes will be determined by negotiations among AMRI and the initial purchasers of the notes. When issued, the notes will be unsecured senior obligations of AMRI. AMRI expects to pay interest on the notes semi-annually on May 15 and November 15 of each year, commencing May 15, 2014. The notes will mature on November 15, 2018, unless earlier repurchased or converted into cash in accordance with their terms prior to such date. The notes will be convertible at the option of the holders only in certain circumstances and solely into cash. The notes will not be convertible into AMRI's common stock or any other security under any circumstances. AMRI will not have the right to redeem the notes prior to maturity.

In connection with the pricing of the notes, AMRI intends to enter into privately negotiated cash convertible note hedge transactions with one or more of the initial purchasers of the notes or their respective affiliates (the "option counterparties"). The initial strike price of the cash convertible note hedge transactions is expected to be the same as the initial conversion price of the note
'/>"/>

SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... Inc. (NASDAQ: GNVC ) today announced the retirement ... of directors effective on October 24, 2014.   Dr. Horovitz joined ... chairman from June 2006 to November 2013.  During his tenure, ... Audit Committees of the board.  "We deeply ... to GenVec, and its stockholders," said Wayne T. Hockmeyer ...
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... June 30 Celsis In Vitro, Inc. (Celsis ... infringement lawsuit against Invitrogen Corporation (Invitrogen) and CellzDirect, Inc. ... Northern District of Illinois in Chicago ... the parent of CellzDirect, is itself a wholly-owned subsidiary ...
... showcasing pharmaceutical, biotechnological and medical device employers in areas ranging from Niagara Falls to ... (Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO ) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040907/CLTU006LOGO ) , ... The leading employment Web site for the life sciences launched the ...
... TargeGen, Inc., a privately held biotechnology company focused on ... the Company has agreed to be acquired by sanofi-aventis (EURONEXT: ... will depend on the achievement of certain future milestones events ... fully realized. The closing of the transaction is expected to ...
Cached Biology Technology:Celsis Seeks Injunction Against Invitrogen for LiverPool(TM) Patent Infringement 2Celsis Seeks Injunction Against Invitrogen for LiverPool(TM) Patent Infringement 3BioSpace Promotes the Northeast Corridor's Life Science Industry 2BioSpace Promotes the Northeast Corridor's Life Science Industry 3Sanofi-aventis to Acquire TargeGen, Inc. 2
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... mating systems, reproductive success reflects phenotypic variation. At ... that of body size and weapon morphology, as ... In a study published in the September issue ... Arizona University) and Jerry F. Husak (Oklahoma State ...
... step toward developing a new type of ultra-sensitive medical ... the skin to detect tiny gold nanorods injected into ... yielded images nearly 60 times brighter than conventional fluorescent ... of biological imaging to study the inner workings of ...
... "shooting stars" of their field. Many research scientists have been ... the blood into diseased organs and replace defective tissue. Such ... of certain muscle diseases. However, a study currently being conducted ... the cells are able to migrate into the muscle fibres, ...
Cached Biology News:Purdue's gold nanorods brighten future for medical imaging 2Research casts doubt on circulating stem cells 2Research casts doubt on circulating stem cells 3
... linear ion trap mass spectrometer enables high-throughput ... The LXQ linear ion trap mass spectrometer ... applications, delivering the fast cycle time and ... trap at an attractive price. The ...
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
... short-term enriched housing for nonhuman primates and ... non-quarantine settings on a per diem basis. ... state-of-the-art social housing and nursery facilities. In ... CDC quarantine facilities. Primate housing and ...
... some the things youll be telling others after ... by Erica Golemis, One look at the table ... topics in protein interaction will tell you immediately ... a part of your personal protein chemistry library. ...
Biology Products: